[go: up one dir, main page]

BRPI9608799B8 - análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica. - Google Patents

análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica. Download PDF

Info

Publication number
BRPI9608799B8
BRPI9608799B8 BRPI9608799A BRPI9608799A BRPI9608799B8 BR PI9608799 B8 BRPI9608799 B8 BR PI9608799B8 BR PI9608799 A BRPI9608799 A BR PI9608799A BR PI9608799 A BRPI9608799 A BR PI9608799A BR PI9608799 B8 BRPI9608799 B8 BR PI9608799B8
Authority
BR
Brazil
Prior art keywords
pro
grf
fatty body
increased biological
pharmaceutical formulation
Prior art date
Application number
BRPI9608799A
Other languages
English (en)
Inventor
Ibea Michel
Brazeau Paul
Abribat Thierry
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27036979&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9608799(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Publication of BRPI9608799B8 publication Critical patent/BRPI9608799B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)

Abstract

"análogo pro-grf - corpo graxo quimérico com aumentada potência biológica, formulação farmacêutica, e, processos para o aumento do nível de hormônio de crescimento, para o diagnóstico de deficiências de hormônio de crescimento, para o tratamento de retardo do crescimento ou ananismo pituitário, de ferida ou cicatrização de ossos e de osteoporose em um paciente, e, para melhoria do anabolismo de proteína em humanos ou animais". a presente invenção refere-se a análogos de pro-grf corpo-graxo quiméricos com aumentada potência biológica, sua aplicação como agentes anabólicos e no diagnóstico e tratamento de deficiências de hormônio de crescimento. os análogos pro-grf -corpo graxo quiméricos incluem uma porção hidrófoba (cauda) e podem ser preparados, ou por ancoragem de uma ou várias caudas hidrófobas ao grf, ou por substituição de um ou vários aminoácidos por um resíduo pseudomicelar na síntese química de grf. os análogos de grf da presente invenção são biodegradáveis, não imunogênicos e demonstram uma melhorada potência anabólica com uma dosagem reduzida e atividade prolongada.
BRPI9608799A 1995-05-26 1996-05-22 análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica. BRPI9608799B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45306795A 1995-05-26 1995-05-26
US65164596A 1996-05-22 1996-05-22
PCT/CA1996/000327 WO1996037514A1 (en) 1995-05-26 1996-05-22 Chimeric fatty body-pro-grf analogs with increased biological potency

Publications (1)

Publication Number Publication Date
BRPI9608799B8 true BRPI9608799B8 (pt) 2019-11-05

Family

ID=27036979

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI9608799A BRPI9608799B8 (pt) 1995-05-26 1996-05-22 análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica.
BRPI9608799-4A BR9608799B1 (pt) 1995-05-26 1996-05-22 análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI9608799-4A BR9608799B1 (pt) 1995-05-26 1996-05-22 análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica.

Country Status (13)

Country Link
US (2) US5939386A (pt)
EP (1) EP0828758B1 (pt)
JP (1) JP3576170B2 (pt)
KR (1) KR100543190B1 (pt)
AT (1) ATE204881T1 (pt)
AU (1) AU697119B2 (pt)
BR (2) BRPI9608799B8 (pt)
CA (1) CA2222068C (pt)
DE (1) DE69614849T2 (pt)
DK (1) DK0828758T3 (pt)
ES (1) ES2163020T3 (pt)
PT (1) PT828758E (pt)
WO (1) WO1996037514A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020311A (en) * 1995-05-26 2000-02-01 Theratechnologies, Inc. GRF analogs with increased biological potency
US6458764B1 (en) * 1995-05-26 2002-10-01 Theratechnologies Inc. GRF analogs with increased biological potency
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
CA2303702A1 (en) * 1999-04-12 2000-10-12 Pfizer Products Inc. Growth hormone and growth hormone releasing hormone compositions
US6759393B1 (en) 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
DK1282437T3 (da) 2000-05-16 2008-06-30 Genentech Inc Behandling af brusklidelser
EP1305338A2 (en) * 2000-08-02 2003-05-02 Theratechnologies Inc. Modified peptides with increased potency
EP1205551A1 (en) * 2000-11-09 2002-05-15 Pfizer Products Inc. Growth hormone and growth hormone releasing hormone compositions
FR2851461B1 (fr) * 2003-02-21 2007-04-20 Seppic Sa Utilisation de n-octanoyl aminoacides comme actif cosmetique et pharmaceutique amincissant
WO2004105789A1 (en) 2003-05-29 2004-12-09 Theratechnologies Inc. Grf analog compositions and their use
ATE536186T1 (de) 2003-09-12 2011-12-15 Tercica Inc Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel
JP4726797B2 (ja) * 2003-10-20 2011-07-20 セラテクノロジーズ・インコーポレーテッド 消耗症に罹患している患者の治療における成長ホルモン放出因子類似体の使用
ES2558928T3 (es) 2007-01-31 2016-02-09 Dana-Farber Cancer Institute, Inc. Péptidos p53 estabilizados y usos de los mismos
BRPI0809366B8 (pt) 2007-03-28 2021-05-25 Harvard College polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica
WO2010121351A1 (en) * 2009-04-20 2010-10-28 Theratechnologies Inc. Use of (hexenoyl trans-3)hgrf(1-44)nh2 and ritonavir in combination therapy
EP2421548A4 (en) * 2009-04-20 2012-09-26 Theratechnologies Inc USE OF (HEXENOYL TRANS-3) HGRF (1-44) NH2 AND SIMVASTATIN IN COMBINED TREATMENT
CA2807685C (en) 2010-08-13 2020-10-06 Aileron Therapeutics, Inc. P53 derived peptidomimetic macrocycle
US20130261058A1 (en) * 2010-09-16 2013-10-03 University Of Miami Acceleration of wound healing by growth hormone releasing hormone and its agonists
MX2013012259A (es) 2011-04-21 2013-11-22 Theratechnologies Inc Analogos del factor de liberacion de la hormona de crecimiento (grf) y usos de estos.
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
NZ627528A (en) 2012-02-15 2016-05-27 Aileron Therapeutics Inc Peptidomimetic macrocycles
CN108912211A (zh) 2012-02-15 2018-11-30 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
CN102702343A (zh) * 2012-06-14 2012-10-03 吉尔生化（上海）有限公司 一种固相合成替莫瑞林的方法
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US8871713B2 (en) * 2013-03-01 2014-10-28 Theratechnologies Inc. Formulations of growth hormone releasing factor (GRF) molecules with improved stability
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
KR20170129879A (ko) 2015-03-20 2017-11-27 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
RU2748576C2 (ru) 2016-04-19 2021-05-27 Гриффон Фармасьютикалз Интернешнл Са. Пэгилированные биологически активные пептиды и их применение
WO2024091863A1 (en) * 2022-10-25 2024-05-02 Starrock Pharma Llc Combinatorial, and rotational combinatorial therapies for obesity and other diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4622312A (en) * 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
CA1271600A (en) * 1985-01-07 1990-07-10 David Howard Coy Growth hormone-releasing peptides and method of treating mammals therewith
US4870054A (en) * 1985-09-27 1989-09-26 Recker Robert R Treatment for osteoporosis using GRF or a biologically active analog thereof
DE3742633A1 (de) * 1987-12-16 1989-06-29 Hoechst Ag Peptide mit beeinflussender wirkung auf die hypophyse von saeugern
IL86102A (en) * 1987-05-11 1994-04-12 Univ Tulane Alkylated growth hormone-releasing peptides and use thereof
FR2622455B1 (fr) * 1987-11-04 1991-07-12 Agronomique Inst Nat Rech Application du facteur de stimulation de la secretion de l'hormone de croissance humaine, de ses fragments actifs et des analogues correspondants, pour augmenter la production laitiere et le poids des nouveau-nes chez les mammiferes
US5065748A (en) * 1989-11-14 1991-11-19 University Of South Florida Method of diagnosing growth hormone disorders employing somatostatin and growth hormone releasing hormone
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
ZA922746B (en) * 1991-04-26 1992-12-30 Lilly Co Eli Superactive grf analogs

Also Published As

Publication number Publication date
AU5683396A (en) 1996-12-11
EP0828758B1 (en) 2001-08-29
BR9608799B1 (pt) 2009-12-01
KR100543190B1 (ko) 2006-06-23
CA2222068C (en) 2007-04-10
ES2163020T3 (es) 2002-01-16
US5861379A (en) 1999-01-19
MX9709098A (es) 1998-06-30
EP0828758A1 (en) 1998-03-18
PT828758E (pt) 2002-02-28
JPH11505807A (ja) 1999-05-25
KR19990021938A (ko) 1999-03-25
ATE204881T1 (de) 2001-09-15
DK0828758T3 (da) 2002-01-07
DE69614849T2 (de) 2002-05-16
US5939386A (en) 1999-08-17
JP3576170B2 (ja) 2004-10-13
AU697119B2 (en) 1998-09-24
BR9608799A (pt) 1999-12-07
DE69614849D1 (de) 2001-10-04
WO1996037514A1 (en) 1996-11-28
CA2222068A1 (en) 1996-11-28

Similar Documents

Publication Publication Date Title
BR9608799B1 (pt) análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica.
ATE311453T1 (de) Grf-analoge mit erhöhter biologischer potenz
ATE204467T1 (de) Orale darreichungsform
AU2000277238A1 (en) Non-mammalian gnrh analogs and uses thereof in tumor cell growth regulation and cancer therapy
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
ES2058411T3 (es) Sustancia fr 901228 y su preparacion.
DE69025920D1 (de) Glykosaminoglykan-modifiertes Protein, Verfahren zu dessen Herstellung und pharmazeutische Zubereitungen, die es enthalten
BG60102B2 (bg) Метод за получаване на 5-флуор-2(((4-циклопропил- метокси-2-пиридинил)метил)тионил)-1н-бензимидазол
DK193887D0 (da) Fysiologisk aktivt peptid
HK16492A (en) Pharmaceutical compositions of somatostatin analogues
DE3650358D1 (de) Diphosphonate enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Arthrosis.
GR3005612T3 (pt)
GB1395090A (en) Stabilized hormone compositions
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
US3670079A (en) Anabolic agents
HUT57204A (en) Process for producing 4-fluoro-2-///4-methoxy-2-pyridinyl/-methyl/-sulfinyl/-1h-benzimidazol with gastric acid secration-diminishing activity and pharmaceutical compositions containing them
ES8700054A1 (es) Procedimiento de obtencion de germicidas a base de acidos clorhidrico y fosforico.
DE3771057D1 (de) Platin enthaltender cytostatischer wirkstoff.
CA2073554A1 (en) Water-soluble composition for sustained-release
ATE25708T1 (de) Biologisch aktive konjugate, ihre herstellung und ihre anwendung.
DK0873134T3 (da) Langvarig frigørelsesformulering omfattende bovin væksthormon frigørende faktor
Vinson et al. α-MSH analogues and adrenal zona glomerulosa function
KR890014745A (ko) Fr-900493화합물과 그 제조방법 및 그를 함유한 의약조성물
ATE39697T1 (de) Erythromycin-a-salz mit mucosecretolytischer und fluidisierender aktivitaet, verfahren zu seiner herstellung und dieses enthaltende pharmazeutische zusammensetzungen.
UA14106A1 (uk) Спосіб профілактики парагрипу молодhяку великої рогатої худоби